SUPERNUS PHARMACEUTICALS, INC. Increase (Decrease) in Deferred Revenue
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Increase (Decrease) in Deferred Revenue of $120.00 thousand for the 12-month period ending 2012-12-31, per its 10-K filed 2013-03-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2013-03-15
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2012-12-31 was -$139.00K, a 153.88% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2012-09-30 was $408.00K.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2012-06-30 was -$91.00K.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for the quarter ending 2012-03-31 was -$58.00K.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2012 was $120.00K, a 82.78% decline from fiscal 2011.
- SUPERNUS PHARMACEUTICALS, INC. increase (decrease) in deferred revenue for fiscal 2011 was $697.00K.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|
| 2012-12-31 | -$139.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $269.00K derived: sum of 2 quarters · filed 2013-03-15 | $178.00K derived: sum of 3 quarters · filed 2013-03-15 | $120.00K 10-K · filed 2013-03-15 |
| 2012-09-30 | $408.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-02 | $317.00K derived: sum of 2 quarters · filed 2012-11-02 | $259.00K 10-Q · filed 2012-11-02 | $517.00K derived: sum of 4 quarters · filed 2013-03-15 |
| 2012-06-30 | -$91.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-13 | -$149.00K 10-Q · filed 2012-08-13 | $109.00K derived: sum of 3 quarters · filed 2013-03-15 | |
| 2012-03-31 | -$58.00K 10-Q · filed 2012-06-08 | $200.00K derived: sum of 2 quarters · filed 2013-03-15 | ||
| 2011-12-31 | $258.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-15 | $697.00K 10-K · filed 2013-03-15 | ||
| 2011-09-30 | $439.00K 10-Q · filed 2012-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |